Doryx MPC is a U.S. branded doxycycline hyclate delayed-release tablet family supplied in 60 mg and 120 mg strengths. “MPC” identifies a particular formulation, not an alternative spelling for every Doryx or generic doxycycline product. The strength numbers are inseparable from this product identity.
The prescribing information makes the key safety distinction explicit: Doryx MPC is not substitutable milligram for milligram with other oral doxycyclines because of differences in bioavailability. The label also explains a specific conversion between Doryx and Doryx MPC products, but that relationship must not be extended to unrelated tablets or capsules.
This page provides the brand-family overview, while Doryx MPC 60 mg and Doryx MPC 120 mg cover the two separate product-strength searches. For all modified-release formulations, see the delayed-release overview.
The product label describes an enteric-coated pellet design with particular acid resistance. This affects how the medication is released and helps explain why an ingredient-only search or an ordinary doxycycline strength field is not sufficient.
Doryx MPC is an antibacterial prescription product when clinically appropriate, unlike the 40 mg Oracea capsule that has a narrow rosacea indication. Sharing the word doxycycline does not mean the two products have the same therapeutic purpose.
Doryx MPC labeling lists 60 mg and 120 mg tablets and specific dosing information for approved clinical uses. The presence of these strengths is a product fact, not permission for a patient to calculate a substitute regimen.
A pharmacy search that returns “doxycycline 120 mg” may be showing Doryx MPC, a delayed-release hyclate tablet. Confirm that full description before comparing it with a conventional 100 mg product.
Official labeling describes Doryx MPC 60 mg as replacing Doryx 50 mg and Doryx MPC 120 mg as replacing Doryx 100 mg in the specified product context. It does not endorse mg-for-mg interchange with all other oral doxycyclines.
Readers should not treat the examples as self-administered conversion instructions. A prescriber and pharmacist must evaluate the actual product switch and revised label directions.
These are product-identity facts, not a regimen calculator or a general conversion rule.
| Label element | Doryx MPC fact | Why it matters |
|---|---|---|
| Active product | Doxycycline hyclate delayed-release tablet | Different from conventional capsules or tablets |
| Strengths | 60 mg and 120 mg | Numbers belong to MPC product identity |
| Substitution | Not mg-for-mg interchangeable with other oral doxycyclines | Prescriber/pharmacist review required |
| Tablet handling | Do not crush or chew | Preserve labeled formulation characteristics |
The Doryx MPC label directs that tablets not be chewed or crushed. Breaking an engineered release formulation without appropriate instructions could change how a dose is delivered.
Administration counseling can also include adequate fluids to reduce esophageal irritation, plus product-specific food instructions. The patient should follow the labeled product and pharmacist, not advice copied from a conventional capsule.
A pharmacy may offer an approved generic with a suitable regulatory basis or another product after prescriber discussion. Substitution decisions must consider formulation and therapeutic-equivalence details, not simply active ingredient and number.
The FDA Orange Book is useful for comparing approved products; it is not a stock checker. Ask the dispensing pharmacist for the precise item proposed and the justification for any change.
The U.S. Doryx MPC prescribing information includes a March 2025 update to its severe skin-reaction warning. Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, exfoliative dermatitis and serious fixed drug eruptions have been reported with doxycycline. These uncommon but potentially dangerous reactions are not merely cosmetic concerns; a painful or rapidly spreading rash, blistering, mouth or eye involvement, or a rash accompanied by fever calls for urgent clinical evaluation.
The label advises immediate discontinuation of Doryx MPC if a severe skin reaction occurs and institution of appropriate treatment. Patients with a suspected severe reaction should seek urgent medical care and inform the treating team of the exact medicine; a pharmacy brand change is not a remedy. This warning is separate from more familiar doxycycline photosensitivity and must not be overlooked when reviewing the specialized MPC product.
An insurer may handle a branded modified-release product differently from conventional generic doxycycline, with differing formulary tiers or required steps. No fixed price or insurer approval can be inferred from the brand name.
Before paying, confirm the exact release product, package quantity, plan restrictions and the total pharmacy charge. For a general plan overview see doxycycline insurance coverage.
If a label or pharmacy offer drops “MPC” from the name, ask whether it refers to the same approved formulation. Confirm 60 or 120 mg, the delayed-release designation and that the prescriber’s directions correspond to the product actually supplied.
Any unexpected change should be resolved before taking the medicine. The strongest product-specific distinction here is not a price or package appearance but the label’s bioavailability-based noninterchangeability warning.
It contains doxycycline hyclate in a particular delayed-release tablet formulation.
Its U.S. label lists 60 mg and 120 mg tablets.
No. The MPC formulation and its approved labeling must be considered.
No. The label specifically warns against mg-for-mg substitution with other oral doxycyclines.
No. The Doryx MPC label says not to crush or chew the tablets.
No. Product records do not confirm a pharmacy’s current inventory.
No. Any change requires appropriate professional review and instructions.